Literature DB >> 8035189

Studies on the characterization of the inhibitory mechanism of 4'-alkylated 1-methyl-4-phenylpyridinium and phenylpyridine analogues in mitochondria and electron transport particles.

M R Gluck1, S K Youngster, R R Ramsay, T P Singer, W J Nicklas.   

Abstract

1-Methyl-4-phenylpyridinium (MPP+), the toxic agent in MPTP-induced dopaminergic neurotoxicity, is thought to act by inhibiting mitochondrial electron transport at complex I. This study examined this latter action further with a series of 4'-alkylated analogues of MPP+. These derivatives had IC50 values that ranged from 0.5 to 110 microM and from 1.6 to 3,300 microM in mitochondria and electron transport particles (ETPs), respectively. The IC50 values of corresponding 4'-alkylated phenylpyridine derivatives to inhibit NADH-linked oxidation ranged from 10 to 205 microM in mitochondria and from 1.7 to 142 microM in ETPs. The potencies of both classes of inhibitors directly correlated with their ability to partition between 1-octanol and water. In mitochondria, increased hydrophobicity resulted in greater inhibition of NADH dehydrogenase but a smaller dependence on the transmembrane electrochemical gradient for accumulation of the pyridiniums as evidenced by an approximately 600-fold, versus only a 36-fold, increase in the IC50 of MPP+ versus 4'-pentyl-MPP+, respectively, in the presence of uncoupler. In ETPs, the analogous increase in potencies of the more hydrophobic analogues was also consistent with an inhibitory mechanism that relied on differential partitioning into the lipid environment surrounding NADH dehydrogenase. However, the pyridinium charge must play a major role in explaining the inhibitory mechanism of the pyridiniums because their potencies are much greater than would be predicted based solely on hydrophobicity. For example, in ETPs, 4'-decyl-MPP+ was nearly 80-fold more potent than phenylpyridine although the latter compound partitions twice as much into 1-octanol.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035189     DOI: 10.1046/j.1471-4159.1994.63020655.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  12 in total

1.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.

Authors:  M R Owen; E Doran; A P Halestrap
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.

Authors:  Hironori Yokoyama; Ryohei Yano; Hayato Kuroiwa; Tatsuya Tsukada; Hiroto Uchida; Hiroyuki Kato; Jiro Kasahara; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2010-04-28       Impact factor: 3.584

Review 3.  Role of glial cells in neurotoxin-induced animal models of Parkinson's disease.

Authors:  Hironori Yokoyama; Hiroto Uchida; Hayato Kuroiwa; Jiro Kasahara; Tsutomu Araki
Journal:  Neurol Sci       Date:  2010-11-24       Impact factor: 3.307

4.  N-Methyl-4-phenylpyridinium Scaffold-Containing Lipophilic Compounds Are Potent Complex I Inhibitors and Selective Dopaminergic Toxins.

Authors:  Bryan Lickteig; Virangika K Wimalasena; Kandatege Wimalasena
Journal:  ACS Chem Neurosci       Date:  2019-04-10       Impact factor: 4.418

Review 5.  Phospholipases A2 in ischemic and toxic brain injury.

Authors:  A Sapirstein; J V Bonventre
Journal:  Neurochem Res       Date:  2000-05       Impact factor: 3.996

6.  Inhibition of complex I by hydrophobic analogues of N-methyl-4-phenylpyridinium (MPP+) and the use of an ion-selective electrode to measure their accumulation by mitochondria and electron-transport particles.

Authors:  M P Murphy; M J Krueger; S O Sablin; R R Ramsay; T P Singer
Journal:  Biochem J       Date:  1995-03-01       Impact factor: 3.857

7.  4-(4-(dimethylamino)phenyl)-1-methylpyridinium (APP+) is a fluorescent substrate for the human serotonin transporter.

Authors:  Ernesto Solis; Igor Zdravkovic; Ian D Tomlinson; Sergei Y Noskov; Sandra J Rosenthal; Louis J De Felice
Journal:  J Biol Chem       Date:  2012-01-30       Impact factor: 5.157

8.  Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.

Authors:  Hironori Yokoyama; Ryohei Yano; Hayato Kuroiwa; Tatsuya Tsukada; Hiroto Uchida; Hiroyuki Kato; Jiro Kasahara; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2010-10-19       Impact factor: 3.584

9.  Mapping the alterations in glutamate with GluCEST MRI in a mouse model of dopamine deficiency.

Authors:  Puneet Bagga; Rachelle Crescenzi; Guruprasad Krishnamoorthy; Gaurav Verma; Ravi Prakash Reddy Nanga; Damodar Reddy; Joel Greenberg; John A Detre; Hari Hariharan; Ravinder Reddy
Journal:  J Neurochem       Date:  2016-10-16       Impact factor: 5.372

10.  Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

Authors:  Peter Klivenyi; Gabrielle Gardian; Noel Y Calingasan; Lichuan Yang; M Flint Beal
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.